Lung Cancer

Beth Sandy, MSN, CRNP, discusses the evolving treatment landscape in small cell lung cancer.

Joshua K. Sabari, MD, discusses the need for additional biomarkers of response to immunotherapy in driver-negative advanced non–small cell lung cancer.

The FDA has granted a breakthrough therapy designation to osimertinib for the adjuvant treatment of patients with stage IB, II, and IIIA EGFR-mutated non–small cell lung cancer following complete resection with curative intent.

Joshua K. Sabari, MD, discusses a number of immunotherapy regimens that have emerged in the frontline setting for patients with driver-negative advanced non–small cell lung cancer; however, for many patients, the decision comes down to pembrolizumab monotherapy or pembrolizumab in combination with platinum-doublet chemotherapy.

Hutchinson China Meditech Limited announces that The China National Medical Products Administration granted priority review to the new drug application for the MET inhibitor savolitinib for the treatment of patients with non–small cell lung cancer with MET exon 14 skipping mutations.

The phase 2 ZENITH20 trial evaluating poziotinib in previously treated patients with non–small cell lung cancer and HER2 exon 20 insertion mutations met its prespecified primary end point.

Paul A. Bunn, Jr, MD, highlights encouraging data with fam-trastuzumab deruxtecan-nxki in HER2-mutant non–small cell lung cancer.

Anne Chiang, MD, PhD, discusses unanswered questions with immunotherapy in non–small cell lung cancer.

Although platinum-based chemotherapy given concurrently with a PD-L1 inhibitor has become the standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer, investigators have found that maintenance immunotherapy and combination strategies have fallen short of expectations.

The introduction of tyrosine kinase inhibitor therapy earlier in the treatment timeline for patients with EGFR-mutant non–small cell lung cancer holds the promise of improving overall survival for this patient population.

David R. Gandara, MD, discusses the current state of tumor mutational burden in lung cancer, ongoing research further examining the utility of this biomarker, and challenges to address with future research.

In our exclusive interview, Jonathan W. Riess, MD, MS, discusses the excitement surrounding KRAS G12C inhibitors in non–small cell lung cancer, preliminary efficacy and safety data with AMG 510, and additional research regarding co-mutations and combinations that could lead to further refinement of the potential role of the agent in the landscape.

Under a draft recommendation proposed by the US Preventive Services Task Force, individuals who are at a high risk for developing lung cancer because of their smoking history would begin annual screening with low-dose computed tomography at age 50 rather than the current clinical standard of 55 years.

Martin Reck, MD, PhD, discusses ​safety data from the ​phase 3 CheckMate-9LA trial in metastatic or recurrent non–small cell lung cancer.

Suresh S. Ramalingam, MD, FASCO, discusses the utility of nivolumab plus ipilimumab in metastatic or recurrent non–small cell lung cancer.

Paul Baas, MD, PhD, discusses recent updates in immuno-oncology within the field of mesothelioma.

Benjamin P. Levy, MD, discusses the efficacy of crizotinib (Xalkori) versus entrectinib in ROS1-rearranged lung cancer.

Michael R. Shafique, MD, discusses the dose escalation and expansion of pepinemab in the phase 1b/2, single arm, first-in-human, CLASSICAL-Lung study in advanced non-small cell lung cancer.

Charu Aggarwal, MD, MPH, discusses the current state of treatment for patients with ALK-positive non–small cell lung cancer, the utility of liquid biopsy, and remaining questions that need to be addressed in the space.

Although antibody-drug conjugates have yet to receive regulatory approval in the lung cancer space, several emerging agents are showing early promise in clinical trials.

Ignacio I. Wistuba, MD, discusses the clinical importance of histological subtyping of lung cancer and additional parameters such as driver alterations, alternative methods for molecular testing, and immunotherapy-related biomarkers have strengthened the diagnostic and treatment paradigms in lung cancer.

In non–small cell lung cancer, single cell analytics, genome editing, and next-generation animal models represent just some of the modern modalities advancing translational research.

The disease-free survival benefit observed with the third-generation EGFR TKI osimertinib as an adjuvant treatment in patients with EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial is striking.

Charu Aggarwal, MD, MPH, discusses emerging treatment approaches in ALK-positive non–small cell lung cancer.